ArticleChemistry & biodiversity2026
Potential of Eugenia brejoensis (Mazine) Essential Oil in Combating Multidrug-Resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Plant Monoterpenes Geraniol, Eugenol and Carvacrol Against Multidrug-Resistant ESKAPE Isolates from Surgical Wounds.Antibiotics (Basel, Switzerland) · 2026Article
- Potential of Eugenia brejoensis (Mazine) Essential Oil in Combating Multidrug-Resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa.Chemistry & biodiversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The genus Eugenia has a long history of use in traditional medicine for treating various conditions, including infectious diseases, gastrointestinal disorders, and skin problems. Essential oils derived from Eugenia species are known for their medicinal properties and have been studied for their antimicrobial and bioactive potential. This study aimed to evaluate, through in vitro tests, the antibacterial, antibiofilm, and antibiotic-modulating effects of Eugenia brejoensis essential oil (EOEb) against multidrug-resistant (MDR) clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa from COVID-19 patients. In addition, we sought to analyze its toxicity and survival rates through in vivo tests in an invertebrate model using Tenebrio molitor. The EOEb was extracted via hydrodistillation and analyzed by gas chromatography-mass spectrometry (GC-MS) and flame ionization detector (FID). Clinical isolates of A. baumannii and P. aeruginosa were identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), and their resistance profiles were determined using the Vitek 2 system. The in vitro tests were conducted using the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined using microdilution and plating methods. Biofilm formation and inhibition assays were performed using crystal violet staining. Synergistic effects of EOEb with ciprofloxacin and gentamicin were evaluated using the checkerboard assay. The antibacterial effect of EOEb was tested in vivo using the T. molitor (mealworm) larvae model to assess toxicity and survival rates. The major constituents of EOEb were rosifoliol (16.47%), guaiol (12.69%), and (E)-caryophyllene (11.97%). All bacteria exhibited an MDR profile. EOEb showed significant antibacterial activity against MDR strains, with MIC and MBC values ranging from 0.512 to 4.096 mg/mL. It also effectively inhibited biofilm formation at concentrations between 0.512 and 4.096 mg/mL. EOEb exhibited synergistic effects with ciprofloxacin against A. baumannii and with gentamicin against P. aeruginosa, as indicated by fractional inhibitory concentration (FIC) indices close to 0.5. The EOEb demonstrated low toxicity in the T. molitor model, with a survival rate of approximately 70%. The EOEb exhibits notable antimicrobial and biofilm-inhibiting properties against MDR pathogens. Its low toxicity and synergistic effects with conventional antibiotics suggest its potential as a therapeutic alternative for combating antibiotic-resistant infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.